News Room
TP-102 clinical study will be presented on the Bacteriophage Therapy Summit 2021
Technophage will be presenting the first information on the recently initiated TP-102 clinical study at the Bacteriophage Therapy Summit 2021 -...
TechnoPhage initiates Phase I/IIa study of TP-102 bacteriophage treatment for diabetic foot infections
TechnoPhage announced the beginning of Phase I/IIa study (REVERSE) of TP-102, a phage therapy candidate for the treatment of Diabetic Foot...
Manuel Garrido will attend Phage Futures Congress 2021
TechnoPhage’s Production Specialist, Manuel Garrido, will attend the Phage Futures Virtual Congress 2021. Manuel will participate in the panel...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology